Lobe Sciences Announces Additional Details Regarding the Acquisition of Altemia(TM) & Company
Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023Acquisition also Includes an International License Agreement With Double Digit Royalty and Milestone Payments and Commercial Inventory and Intellectual Property.Vancouver, British Columbia--(Newsfile Corp. - June 30, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American...
2023-06-30 10:03 PM EDT
Lobe Sciences, Ltd. Provides Update on Vitamind
Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today provides an update on its acquisition of the Vitamind Brand and intellectual property ("Vitamind") pursuant to an asset purchase agreement dated April 30, 2021 (the "Agreement"). Pursuant to the Agreement, the Company issued 2,916,668[1] common shares to acquire Vitamind. The Agreement specified...
2023-04-21 5:00 PM EDT
Lobe Sciences, Ltd. Announces the Acquisition of Altemia(TM) & Company
Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023Acquisition also Includes an International License Agreement With Double Digit Royalty and Milestone Payments, Commercial Inventory and Intellectual Property.Vancouver, British Columbia--(Newsfile Corp. - April 18, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical...
2023-04-18 8:58 AM EDT
Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023
Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that Philip Young, CEO and Executive Chairman, will present at the SEQUIRE CANNABIS & PSYCHEDELICS CONFERENCE, April 5th at 10:00AM EDT.Registration for the event is accessible via the following link Sign up free.About Lobe Sciences Ltd.Lobe Sciences is a biopharmaceutical company focused...
2023-04-04 8:00 AM EDT
Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that its exclusive commercial manufacturing partner has received their initial 2023 quota for our novel psilocin drug product (L-130) from the Drug Enforcement Administration (DEA). Mr. Philip J. Young, Chairman and Chief Executive Officer of the Company stated, "This is...
2023-03-22 9:01 AM EDT
Lobe Sciences Ltd. Announces Exclusive Collaboration with Quality Chemical Laboratories LLC
Quality Chemical Laboratories LLC ("QCL") has developed a synthetic pathway for psilocybin, psilocin and psilocin analogues exclusively for Lobe SciencesQCL agrees to supply Lobe Sciences research and commercial quantities of two new chemical entities, L-130 and L-131 under an exclusive arrangement Lobe Sciences Ltd. and QCL have entered into an agreement for the development of commercial formulations of L-130 for the treatment of chronic cluster headacheVancouver, British Columbia--(Newsfile Corp. - February 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB:...
2023-02-21 8:30 AM EST
Lobe Sciences, Ltd. Announces USD$250,000 Convertible Note Financing and Warrant Issuance
Vancouver, British Columbia--(Newsfile Corp. - February 10, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain disease today announced a financing in the amount of USD $250,000. This investment will be in the form of a convertible note (the "Note") with a face value of USD $250,000 and simple interest at the annual rate of 11.0% per annum. The...
2023-02-10 5:03 PM EST
Lobe Sciences Congratulates Australia for Becoming the First Nation to Approve the Medicinal Use of Psilocybin and MDMA
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today congratulated the people of Australia for the decision by the TGA (Therapeutic Goods Administration) to reschedule Psilocybin and MDMA so that trained physicians may prescribe the psychedelics for patients across the country.Philip J. Young, Chairman and Chief Executive Officer of the...
2023-02-06 8:00 AM EST
Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain disease, today announced that it has signed an Investigator Initiated Research Agreement with Lauren R. Natbony, MD, FAHS, Founder and Medical Director of Integrative Headache Medicine of New York, to study the tolerability and efficacy of our proprietary psilocin compound L-130, in patients...
2023-01-26 8:30 AM EST
Lobe Sciences Board of Directors Elects to Receive Shares in Lieu of Cash for All Board Fees
Endorsement underscores transition into a fully integrated biotechnology companyVancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced its Board of Directors voted to receive shares in Lobe in lieu of the traditional cash renumeration. Philip J. Young, Chairman and Chief Executive Officer of the Company stated, "This is a...
2023-01-23 9:00 AM EST
Lobe Sciences Provides Update For 2023 Milestones
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient focused psychedelic derived medicines for neurologic and brain disease today announced an updated overview for 2023.Mr. Philip Young, Chairman and Chief Executive Officer of the Company, stated, "2022 was a productive year for Lobe Sciences. We increased our intellectual property portfolio with several new chemical entities (NCEs) derived...
2023-01-18 7:00 AM EST
Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced an update for its clinical development plans for its proprietary Psilocin based compound L-130.Philip J. Young, Chairman and Chief Executive Officer of the Company stated, "Subsequent to our last communication on the cGMP production of L-130, I wanted to update...
2022-11-30 9:12 AM EST
Lobe Sciences to Present at MONEYSHOW VIRTUAL EXPO November 10, 2022
Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") today announced that Philip Young, CEO and Executive Director, will present at the MONEYSHOW VIRTUAL EXPO, November 10th at 10:40AM EDT.The presentation will be available on demand through the MONEYSHOW VIRTUAL EXPO Meeting site at this link, Lobe Sciences is Developing Psychedelic Derived Medicines for Neurologic and Brain Disease.Registration for the event is accessible via the following link Free...
2022-11-08 9:20 AM EST
Lobe Sciences Announces the Completion of cGMP Production of Clinical Supplies For Upcoming Clinical Trials
Vancouver, British Columbia--(Newsfile Corp. - October 13, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that it has completed the synthesis of bulk L-130, a proprietary form of psilocin, and of the clinical supplies to be used in upcoming trials. The L-130 was manufactured in compliance with U.S. cGMPs (Current Good Manufacturing Practices). Philip J. Young,...
2022-10-13 8:00 AM EDT
Lobe Sciences Announces the Appointment of Baxter F. Phillips III to Its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - October 5, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that Baxter F. Phillips III has been appointed to the Board of Directors of the Company, effective October 3, 2022. Mr. Phillips has more than 20 years of experience leading multinational corporate strategy and finance in the biotechnology and pharmaceutical industry....
2022-10-05 9:08 AM EDT
Lobe Sciences Announces the Expansion of its Patent Portfolio with International Filings
Vancouver, British Columbia--(Newsfile Corp. - October 3, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that it has expanded its patent portfolio through the filing of international patents in Canada, the United States, Europe and Australia for Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury...
2022-10-03 5:30 PM EDT
Lobe Sciences Announces Incorporation of Australian Subsidiary
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has incorporated Lobe Sciences Australia Pty Ltd., a 100% owned Australian subsidiary of the Company, to facilitate the three or more clinical trials in Australia with newly announced partner iNGENū Pty Ltd. The trials aim to evaluate Lobe's proprietary psilocin...
2022-09-23 8:00 AM EDT
Lobe Sciences Announces Closing of Private Placement
Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease, today announced that it has closed a non-brokered private placement of units (the "Units") for gross proceeds of $1,347,500 (the "Offering"). "We are extremely pleased to close this financing and are thankful for the support and confidence of our investors who join...
2022-09-08 2:55 PM EDT
Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia
Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into a term sheet contemplating convertible note financing bearing interest at 15% per annum with a term of 12 months (the "Convertible Notes") with Cantheon Capital ("Cantheon") for aggregate proceeds to the Company of up to USD$1,500,000 to...
2022-09-01 9:21 AM EDT
Lobe Sciences Announces Update on Corporate Slide Deck Highlighting its Psilocin Compounds and Development Plans
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has updated its Corporate Slide Deck which among other initiatives, describes its plans for advancing the development of its psilocin analogues L-130 and L-131.Philip Young, CEO of Lobe Sciences stated, "We have made significant progress toward initiating our first human...
2022-08-19 9:24 AM EDT